Zhang Y - Search Results

1

ENPP2 promotes progression and lipid accumulation via AMPK/SREBP1/FAS pathway in chronic lymphocytic leukemia.

Lu L, Hu X, Han Y, Wang H, Tian Z, Zhang Y, Wang X. Lu L, et al. Among authors: zhang y. Cell Mol Biol Lett. 2024 Dec 27;29(1):159. doi: 10.1186/s11658-024-00675-6. Cell Mol Biol Lett. 2024. PMID: 39731014 Free PMC article.

2

Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51.

Han Y, Hu X, Yun X, Liu J, Yang J, Tian Z, Zhang X, Zhang Y, Wang X. Han Y, et al. Among authors: zhang x, zhang y. Cell Death Dis. 2021 Nov 15;12(11):1083. doi: 10.1038/s41419-021-04368-2. Cell Death Dis. 2021. PMID: 34782617 Free PMC article.

3

Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.

Zhang Y, Zhou X, Li Y, Xu Y, Lu K, Li P, Wang X. Zhang Y, et al. Oncogene. 2018 Oct;37(41):5520-5533. doi: 10.1038/s41388-018-0333-x. Epub 2018 Jun 12. Oncogene. 2018. PMID: 29895969

4

Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.

Xu Y, Zhou X, Li Y, Zhang Y, Wang X. Xu Y, et al. Among authors: zhang y. Leuk Lymphoma. 2019 May;60(5):1266-1274. doi: 10.1080/10428194.2018.1523400. Epub 2019 Feb 4. Leuk Lymphoma. 2019. PMID: 30714848

5

Targeting the Wnt/β-catenin signaling pathway in cancer.

Zhang Y, Wang X. Zhang Y, et al. J Hematol Oncol. 2020 Dec 4;13(1):165. doi: 10.1186/s13045-020-00990-3. J Hematol Oncol. 2020. PMID: 33276800 Free PMC article. Review.

6

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia.

Yun X, Sun X, Hu X, Zhang H, Yin Z, Zhang X, Liu M, Zhang Y, Wang X. Yun X, et al. Among authors: zhang h, zhang x, zhang y. Front Oncol. 2021 Jul 1;11:698572. doi: 10.3389/fonc.2021.698572. eCollection 2021. Front Oncol. 2021. PMID: 34277446 Free PMC article.

7

Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Nie Y, Yun X, Zhang Y, Wang X. Nie Y, et al. Among authors: zhang y. Exp Hematol Oncol. 2022 Jun 27;11(1):39. doi: 10.1186/s40164-022-00292-z. Exp Hematol Oncol. 2022. PMID: 35761419 Free PMC article. Review.

8

Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model.

Zhang X, Han Y, Hu X, Wang H, Tian Z, Zhang Y, Wang X. Zhang X, et al. Among authors: zhang y. Biomark Res. 2022 Oct 21;10(1):75. doi: 10.1186/s40364-022-00423-y. Biomark Res. 2022. PMID: 36271413 Free PMC article.

9

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.

Tian Z, Liu M, Zhang Y, Wang X. Tian Z, et al. Among authors: zhang y. J Hematol Oncol. 2021 May 3;14(1):75. doi: 10.1186/s13045-021-01084-4. J Hematol Oncol. 2021. PMID: 33941237 Free PMC article. Review.

10

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.

Yun X, Zhang Y, Wang X. Yun X, et al. Among authors: zhang y. Biomark Res. 2020 Sep 7;8:40. doi: 10.1186/s40364-020-00222-3. eCollection 2020. Biomark Res. 2020. PMID: 32939265 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260,202 results

Search Page

Filters